Read by QxMD icon Read


Aida Siyahian, Saad Ullah Malik, Adeela Mushtaq, Carol L Howe, Aneela Majeed, Tirdad Zangeneh, Samar Iftikhar, Shahid Habib, Umar Zahid, Irbaz Bin Riaz, Zabih Warraich, Warda Faridi, Faiz Anwer
Patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) are at a very high risk of hepatitis B virus reactivation (HBVr). Lamivudine is commonly used as prophylaxis against HBVr in high risk patients undergoing allo-HSCT. Unfortunately, its efficacy is diminishing due to the development of HBV mutant drug resistant strains. With the availability of newer antiviral agents like Entecavir, Telbivudine, Adefovir and Tenofovir, it is important to assess their role in HBVr prophylaxis. A comprehensive search of seven databases was performed to evaluate efficacy of antiviral prophylaxis against HBVr in allo-HSCT patients (PubMed/Medline, Embase, Scopus, Cochrane Library, Web of Science, CINAHL, and ClinicalTrials...
March 12, 2018: Biology of Blood and Marrow Transplantation
Zobair M Younossi, Maria Stepanova, Harry L A Janssen, Kosh Agarwal, Mindie H Nguyen, Ed Gane, Naoky Tsai, Issah Younossi, Andrei Racila
BACKGROUND AND AIM: Chronic infection with hepatitis B virus (HBV) causes liver disease and cirrhosis. It is not clear how treatment of chronic HBV infection affects patient-reported outcomes (PROs). We aimed to assess changes in PROs in patients treated for chronic HBV infection. METHODS: We collected and analyzed PRO data from 242 patients with chronic HBV infection (without advanced fibrosis or cirrhosis) enrolled in 2 international phase 2 blinded controlled clinical trials from 2015 through 2017...
March 2, 2018: Clinical Gastroenterology and Hepatology
Chengliang Zhou, Ying Yu, Qian Yang, Huihui Wang, Min Hou, Li Jin, Fanghong Zhang, Jiangzhong Sheng, Mingfang Miao, Xiaofu Yang, He-Feng Huang
Telbivudine is an orally nucleoside analog with potent and specific antihepatitis B virus (HBV) activity, and it has been reported to block mother-to-infant transmission. However, few studies have focused on the safety of prenatal exposure for offspring development.This is a prospective noninterventional study. Participants were enrolled during delivery through the Women's Hospital of Zhejiang University School of Medicine between January 2012 and September 2013. Neonate's umbilical cord arterial blood (UCAB) was collected after delivery...
March 2018: Medicine (Baltimore)
Jian Wu, Fang Yin, Xinmin Zhou
The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir...
March 1, 2018: Acta Pharmaceutica
Dejuan Sun, Lingjuan Zhu, Dahong Yao, Lixia Chen, Leilei Fu, Liang Ouyang
Hepatitis B virus (HBV) infections affect about 240 million patients worldwide and increase the risk of liver cirrhosis and hepatocellular carcinoma. It is estimated that about 686 thousand people died annually of liver damage resulted from HBV infections. At present, two classes of antiviral drugs have been approved by the Food and Drug Administration (FDA) for the treatment of hepatitis B, immunomodulators (interferon [IFN]-a and pegylated-interferon [PEG-IFN]-a) and nucleos(t)ide analogs (lamivudine, telbivudine, adefovir, tenofovir [TDF], and entecavir [ETV])...
February 5, 2018: European Journal of Medicinal Chemistry
Petr Husa, Jan Šperl, Petr Urbánek, Soňa Fraňková, Stanislav Plíšek, Petr Kümpel, Luděk RoŽnovský
The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2014. The basis for these guidelines were the European Association for the Study of the Liver guidelines from April 2017. According to qualified estimates, there are 240 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest seroprevalence study, 0.56 % of the Czech citizens were chronically infected with HBV in 2001...
December 2017: Klinická Mikrobiologie a Infekc̆ní Lékar̆ství
Chao-Wei Hsu, Yi-Cheng Chen, Ming-Ling Chang, Chen-Chun Lin, Shi-Ming Lin, Wei-Ting Chen, Yu-De Chu, Chau-Ting Yeh
Background: Besides antiviral activities against hepatitis B virus (HBV), telbivudine has an extrahepatic pharmaceutical effect: to improve renal function assessed by estimated glomerular filtration rate (eGFR). However, the durability of this effect after withdrawal of telbivudine or switching to other antivirals has never been investigated. Methods: We conducted a postmarketing, real-world observation study for telbivudine treatment. The durability of telbivudine-associated renal function improvement was examined following withdrawal/switching of antivirals...
January 2018: Open Forum Infectious Diseases
G L-H Wong, W-K Seto, V W-S Wong, M-F Yuen, H L-Y Chan
BACKGROUND: Safety profile of nucleos(t)ide analogues is an important issue in view of its widespread use for decades in patients with chronic hepatitis B (CHB). AIM: To review and evaluate the latest evidence on the safety profiles of the six approved nucleoside analogues. METHODS: Relevant articles related to nucleoside analogue safety were selected for review following extensive language- and date-unrestricted, electronic searches of the literature...
January 22, 2018: Alimentary Pharmacology & Therapeutics
Tianyu He, Yuqing Bai, Haodong Cai, Xiaojuan Ou, Min Liu, Wei Yi, Jidong Jia
BACKGROUND: Few data exist regarding use of nucleos(t)ide analogs started in early pregnancy for mothers with active chronic hepatitis B (CHB). We assessed the safety and efficacy of lamivudine/telbivudine initiated in the first trimester versus no treatment in mothers with active CHB. METHODS: We retrospectively enrolled 94 mothers newly diagnosed with active CHB in the first trimester of pregnancy. Patients with or without antiviral therapy were followed until postpartum week 28...
January 17, 2018: Hepatology International
X D Luo, X P Chen, X F Chen
Objective: To investigate the optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B (CHB) after suboptimal response to 24 weeks of pegylated interferon (Peg-IFN) α-2a. Methods: A total of 188 patients with HBeAg-positive CHB who had suboptimal response to 24 weeks of Peg-IFN α-2a were randomly divided into entecavir group (n = 93) and telbivudine group (n = 95). The two groups received entecavir 0.5 mg/d and telbivudine 0.6 g/d, respectively, for 208 weeks. After 208 weeks of treatment, the following indices were assessed: HBeAg clearance rate and seroconversion rate, hepatitis B virus (HBV) DNA clearance rate (HBV DNA < 500 IU/ml), safety, and drug resistance rate...
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
Qing-Lei Zeng, Guang-Hua Xu, Ben Wang, Zhi-Qin Li, Zu-Jiang Yu
Many studies have demonstrated that antiviral therapy has an important role in the prevention of mother-to-child transmission of hepatitis B virus (HBV)1-3 , including a recent article by Han et al. who reported that the majority of mothers stopped prophylactic telbivudine at 1 month postpartum.4 However, the HBV Guidelines of the AASLD (at delivery to 3 months postpartum),1 EASL (within and at 12 weeks postpartum in 2012 and 2017, respectively),2 and APASL (at delivery)3 had different recommendations regarding stopping time of antivirals given as prophylaxis, which result in differing durations worldwide...
December 23, 2017: Journal of Viral Hepatitis
Jie Chen, Detian Li
Renal fibrosis yields decreased renal function and is a potent contributor to chronic kidney disease (CKD). Telbivudine (LdT) is an anti-hepatitis B virus (HBV) drug that has been found to steadily improve renal function, but the mechanism of drug action is unclear. One explanation is that LdT impacts inflammatory or fibrotic pathways. In this study, we investigated renal protection by LdT in a rat model of unilateral ureteral obstruction (UUO). UUO rats received oral gavage of LdT (1, 1.5, or 2g/kg/day) for 5weeks...
February 2018: International Immunopharmacology
Y Hu, C Xu, B Xu, L Hu, Q Liu, J Chen, J Liu, L Liu, J Yang, T Chen, J Wen, N Jiang, Y Zhang, M Cao, J Feng, X Lin, Z Wang, B Xu, Y-H Zhou
Infection of hepatitis B virus (HBV) occurs in ~10% of infants of HBV-infected mothers with positive hepatitis B e antigen (HBeAg) after immunoprophylaxis. We aimed to evaluate the safety and efficacy of telbivudine used during late pregnancy for preventing mother-to-child transmission of HBV. We conducted a multicenter prospective cohort study in 5 hospitals from 2012 to 2014, which enrolled HBV-infected singleton pregnant women with positive HBeAg. By their choice, women were divided into therapy (telbivudine 600 mg/day, from gestation 28-32 weeks to 3-4 weeks postpartum) and control (no antiviral agent) groups...
November 28, 2017: Journal of Viral Hepatitis
Yao-Chun Hsu, Hsiu-J Ho, Teng-Yu Lee, Yen-Tsung Huang, Ming-Shiang Wu, Jaw-Town Lin, Chun-Ying Wu, Hashem B El-Serag
This study aimed to elucidate the temporal change and determinants for the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B continuously receiving nucleos(t)ide analogues. Through analysis of the national healthcare database in Taiwan, we screened a total of 65,426 infected patients receiving entecavir or tenofovir for at least 3 months and excluded those with lamivudine, adefovir or telbivudine exposure, malignancy, end-stage renal failure, or a diagnosis of HCC within 3 months of starting treatment...
November 28, 2017: Journal of Viral Hepatitis
Jinxin Zheng, Minggui Deng, Xiaoliang Qiu, Zhong Chen, Duoyun Li, Xiangbin Deng, Qiwen Deng, Zhijian Yu
BACKGROUND: Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis. However, reported cases of telbivudine leading to multiple organ failure are rare. Here, we report a case of telbivudine-induced severe polymyositis, lactic acidosis, and multiple organ failure. CASE PRESENTATION: A 30-year-old Chinese man with hepatitis B virus infection received antiviral treatment with 600 mg of telbivudine daily for more than 11 months...
November 27, 2017: Journal of Medical Case Reports
Bicui Chen, Li Chen, Cai Cheng, Mingkang Zhong, Xiaojin Shi, Jiming Zhang, Bin Wang
Usually, creatine kinase elevation is commonly reported in telbivudine-treated patients. However, little is known abosut the relationship between this adverse drug reaction and plasma concentration. In this study, a sensitive, rapid and safe quantitative bioanalytical method has been established by using LC-MS/MS for the determination of telbivudine in a clinical study of chronic hepatitis B (CHB) patients. The assay was linear in a dynamic 10-10,000 ng/mL range (r(2) > 0.999) and total analysis time was 6 min in this method...
November 17, 2017: Biomedical Chromatography: BMC
Hong Shi, Zongping Han, Jian Liu, Jinfang Xue, Shuya Zhang, Zhe Zhu, Jinyu Xia, Mingxing Huang
BACKGROUND The antiviral effect of HBV in different nucleos (t) ide analogues is still not well known. This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA. MATERIAL AND METHODS The effective data of 207 patients treated by LMV (n=43), ADV (n=57), LdT (n=54) or ETV (n=53) were collected and analyzed during 144-week follow-up by retrospective analysis...
November 2, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Ignatius R Tenggara, C Rinaldi Lesmana, Rino A Gani
BACKGROUND: Hepatitis B is endemic in Indonesia and treatment response need to be monitored during and after antiviral therapy. Liver stiffness measurement and alanine aminotransferase-to-platelet ratio index (APRI) are noninvasive method to detect liver fibrosis available in Indonesia. However, little is known about their ability to evaluate treatment response in chronic hepatitis B (CHB) patients in Indonesia. This study aimed to investigate liver stiffness changes by transient elastography (TE) and APRI before and after one-year oral antiviral treatment in CHB patients and the correlation between TE and APRI...
July 2017: Acta Medica Indonesiana
J Liu, T Chen, Y Zhao
Hepatitis B virus infection is currently the most important cause of chronic viral hepatitis worldwide and is one of the most frequent causes of end-stage liver disease. With the international implementation of the hepatitis B vaccine and combined prophylaxis for infants born to HBsAg(+) mothers, the prevalence of hepatitis B has decreased remarkably. However, intra-uterine transmission has become a critical bottleneck for eliminating hepatitis B infection. The efficacy of nucleos(t)ide analogs on inhibiting hepatitis B replication has been widely confirmed, and the quality of life and the survival of individuals with chronic hepatitis B (CHB) have improved to a great degree...
November 2017: Journal of Viral Hepatitis
H-Y Pan, H-Y Pan, W-Y Song, W Zheng, Y-X Tong, D-H Yang, Y-N Dai, M-J Chen, M-S Wang, Y-C Huang, J-J Zhang, H-J Huang
Chronic hepatitis B (CHB) patients with higher hepatitis B virus (HBV) load (higher viral load [HVL], HBV DNA ≥1 × 107 copies/mL) require antiviral therapy, but data for evaluating the long-term outcome of this therapy with antiviral agents remain limited. We comparatively evaluated the efficacy and the safety of nucleoside analogues in 179 noncirrhotic CHB patients with HVL over 5 years. The HBeAg-positive (n = 104) or HBeAg-negative (n = 75) patients were treated consecutively with telbivudine (LdT, n = 88) or entecavir (ETV, n = 91) and evaluated for viral response, drug resistance and safety...
November 2017: Journal of Viral Hepatitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"